Prostate cancer is a leading cause of cancer death in men worldwide. Among the various
treatment options, radiopharmaceutical therapy has shown notable success in metastatic …

Prostate cancer (PCa) is the most common malignancy in men of middle and older age. The
standard treatment strategy for PCa ranges from active surveillance in low-grade, localized …

Background: 177LuPSMA is an effective treatment in metastatic castrate-resistant prostate
cancer with trials adopting a standardised dose interval. Adjusting treatment intervals …

Abstract Purpose of Review [177Lu] Lu-PSMA-617 is a radiopharmaceutical that emits beta-
minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate …

Radionuclide Therapy (RNT) with 177Lu-DOTATATE targeting somatostatin receptors
(SSTRs) in neuroendocrine tumours (NET) has been successfully used in routine clinical …

DNA is an organic molecule that is highly vulnerable to chemical alterations and breaks
caused by both internal and external factors. Cells possess complex and advanced …

Simple Summary Neuroendocrine tumor (NET) patients often suffer from metastases,
thereby eliminating surgery as a curative treatment option. A possible treatment strategy for …

Purpose: TRA-1-60 (TRA) is an established transcription factor of embryonic signaling and a
well-known marker of pluripotency. It has been implicated in tumorigenesis and metastases …

A rapid, sensitive, and simple UHPLC-MS/MS method for the determination of the PARP
inhibitor talazoparib in mouse plasma was developed and validated using [13 C, 2 H 4] …

In managing prostate cancer, the integration of multidisciplinary team (MDT) with prostate-
specific membrane antigen (PSMA) theranostics marks a significant advancement …